Figure 5.Pressure preconditioning increased tumor size in A549 xenograft mice, which was blocked by Pembrolizumab. (A) Pressure preconditioning increased tumor size in A549 xenograft mice. N indicates the number of mice and P indicates the P values by unpaired t-test. A549 xenograft tumors were established subcutaneously in athymic nude mice and tumor size was examined every 3 days. (B) PD-L1 antibody pembrolizumab did not affect tumor size in the absence of αROR1-CAR T cells. Pembrolizumab (5 mg/kg) was injected intravenously on day-21. (C) Pressure preconditioning increased tumor size in the presence of αROR1-CAR T cells. αROR1-CAR T cells were injected on day-21 and day-27. (D) Pembrolizumab enhanced the efficacy of αROR1-CAR T cells. Pembrolizumab (5 mg/kg) was injected intravenously on day-21 and day-27. Green arrows indicate adding Pembrolizumab and yellow CAR-T cells. (E) Tumors were surgically removed after sacrificing the mice on day-33 and imaged. (F) Tumors were weighed and statistically analyzed by unpaired t-test. ns, not significant. (G) CAR T cells and pembrolizumab treatment did not affect the bodyweight of xenograft mice. (H) Plasma TNFα levels were increased by combined treatment of CAR-T cells and pembrolizumab.
